Non-Small Cell Lung Carcinoma CRISPR Knockout Cell Models

Lung cancer is the leading cause of cancer death worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020 (WHO). Non-small cell lung carcinoma (NSCLC) accounts for approximately 85% of all lung cancers. The 5-year survival rate for NSCLC ranges from 60-70% for localized disease (stage I) to less than 10% for metastatic disease (stage IV) (NCI SEER). Major risk factors include tobacco smoking (responsible for ~80% of cases), second-hand smoke, radon exposure, and occupational carcinogens. The high mortality and molecular heterogeneity underscore the urgent need for improved preclinical models.

NSCLC is an ideal disease for mechanistic studies due to its well-characterized molecular subtypes (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) and extensive public genomic datasets (TCGA, COSMIC). Key open questions include mechanisms of acquired resistance to targeted therapies, tumor microenvironment interactions, and identification of novel synthetic lethal vulnerabilities. Gene-edited cell models provide a powerful platform to dissect these questions with isogenic controls.

NSCLC pathogenesis involves the activation of oncogenic pathways and inactivation of tumor suppressors. Key pathways include:

• • MAPK/ERK pathway: Activation via KRAS mutations (codons 12, 13, 61) leads to uncontrolled cell proliferation.
• • PI3K/AKT/mTOR pathway: Mutations in PIK3CA or loss of PTEN promote survival and growth.
• • p53 pathway: TP53 mutations (over 50% of NSCLC) impair apoptosis and genomic stability.
• • Cell cycle regulation: CDKN2A loss or CDK4/6 amplification drives cell cycle progression.

The following table summarizes common genetic alterations in NSCLC based on TCGA and COSMIC data:

Deregulated signaling networks in NSCLC include:

• • MAPK/ERK cascade: KRAS -> RAF -> MEK -> ERK. Key nodes: KRAS, BRAF, MAP2K1.
• • PI3K/AKT pathway: PI3K -> AKT -> mTOR. Key nodes: PIK3CA, PTEN, AKT1.
• • Wnt/beta-catenin pathway: CTNNB1 mutations or APC loss lead to nuclear beta-catenin accumulation.
• • JAK/STAT pathway: Activation via IL-6 or mutations in JAK2/STAT3.
• • DNA damage repair: ATM, ATR, BRCA1/2 alterations affect genomic stability.

Commonly used NSCLC cell lines and their key mutations:

Organoid models derived from patient tumors retain stromal architecture and are increasingly used for drug sensitivity testing, though they require complex culture conditions.

Animal models for NSCLC include:

• • Patient-derived xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice. Preserves tumor heterogeneity and histology.
• • Genetically engineered mouse models (GEMM): Conditional KRAS G12D or EGFR L858R expression with Cre-Lox systems. Recapitulates tumor development in immune-competent hosts.
• • Induced models: Carcinogen exposure (e.g., urethane) in mice to generate lung tumors with Kras mutations.
• • Syngeneic models: Mouse lung cancer cell lines (e.g., LLC1) implanted into immunocompetent mice for immunotherapy studies.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53 knockout in A549 cells to study p53 loss-of-function effects.
• • KRAS G12D knock-in in NCI-H460 cells to model oncogenic activation.
• • EGFR T790M knock-in in HCC827 cells to study acquired resistance to EGFR inhibitors.
• • KEAP1 knockout in NCI-H1299 cells to investigate oxidative stress responses.

Commercially available, sequence-verified models accelerate research by eliminating the need for in-house editing and validation. These isogenic pairs allow direct comparison of mutant vs. wild-type effects in an identical genetic background, reducing experimental variability.

Gene-edited cell lines are essential for functional validation of candidate oncogenes and tumor suppressors. For example:

• • Knockout of STK11 in A549 cells confirmed its role in metabolic reprogramming and AMPK signaling.
• • Knock-in of KRAS G12C in NCI-H460 cells enabled studies of mutant-specific inhibitor sensitivity (e.g., sotorasib).
• • TP53 knockout in NCI-H1975 cells demonstrated loss of apoptotic response to DNA-damaging agents.

Isogenic cell pairs are powerful tools for drug screening and resistance modeling:

• • EGFR T790M knock-in models recapitulate resistance to first-generation EGFR inhibitors (e.g., gefitinib) and are used to test third-generation inhibitors (e.g., osimertinib).
• • KRAS G12C isogenic lines enable screening of KRAS G12C inhibitors in a controlled background.
• • Resistance can be induced by chronic drug exposure in edited lines, followed by genomic analysis to identify secondary mutations.

CRISPR-based screens in gene-edited NSCLC cells identify synthetic lethal interactions:

• • KEAP1 knockout lines are vulnerable to glutaminase inhibitors, suggesting a biomarker for patient stratification.
• • STK11 loss sensitizes cells to mTOR inhibitors and phenformin.
• • Genome-wide CRISPR screens in TP53-null cells revealed WEE1 as a synthetic lethal target, leading to clinical trials of adavosertib.

The following databases provide critical genomic, transcriptomic, and functional data for NSCLC research: